NASDAQ: AMRNAmarin Corp PLC Stock
$9.36-0.45 (-4.59%)
Updated Apr 16, 2025
AMRN Price
$9.36
Fair Value Price
-$0.02
Market Cap
$193.84M
52 Week Low
$7.08
52 Week High
$20.60
P/E
-2.34x
P/B
0.4x
P/S
0.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$228.61M
Earnings
-$82.18M
Gross Margin
35.6%
Operating Margin
-33.77%
Profit Margin
-35.9%
Debt to Equity
0.41
Operating Cash Flow
-$31M
Beta
1.1
Next Earnings
Apr 18, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AMRN Overview
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AMRN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
AMRN
Ranked#18 of 18
Ranked#18 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $104.88 | A | |
| $109.58 | A | |
| $49.36 | A |
Be the first to know about important AMRN news, forecast changes, insider trades & much more!
AMRN News
Overview
Due Diligence Score
–
Industry Average (38)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AMRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMRN ($9.36) is overvalued by 42,844.01% relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AMRN ($9.36) is not significantly undervalued (42,844.01%) relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AMRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AMRN due diligence checks available for Premium users.
Valuation
AMRN fair value
Fair Value of AMRN stock based on Discounted Cash Flow (DCF)
Price
$9.36
Fair Value
-$0.02
Undervalued by
42,844.01%
AMRN ($9.36) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AMRN ($9.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AMRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AMRN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.34x
Industry
49.46x
Market
27.87x
AMRN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.4x
Industry
5.76x
AMRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMRN's financial health
Profit margin
Revenue
$62.3M
Net Income
-$48.6M
Profit Margin
-78%
AMRN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AMRN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$685.3M
Liabilities
$199.2M
Debt to equity
0.41
AMRN's short-term assets ($595.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMRN's short-term assets ($595.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMRN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AMRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.3M
Investing
-$22.8M
Financing
$17.0k
AMRN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AMRN vs General Drug Manufacturer Stocks
Amarin Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.